About: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 2000 (uk) im Februar 2000 veröffentlichter wissenschaftlicher Artikel (de) wüsseschaftlicher Artikel, wo im Hornig 2000 veröffentlicht worden isch (gsw) artículu científicu espublizáu en febreru de 2000 (ast) artikull shkencor i botuar më 01 shkurt 2000 (sq) scientific article published on 01 February 2000 (en)
publication date	wds:Q73445633-EFB61C00-B0AF-40CE-B0FF-898162E11C5B
publication date	2000-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73445633-9349A6BF-02D5-40A3-B12A-4D240E9371CB
language of work or name	English
author name string	wds:Q73445633-05C74A7D-DD30-4C3B-8957-1A3DCAF345E5 wds:Q73445633-06E9FE6C-9977-4EC1-8B99-A57F3E3978D2 wds:Q73445633-2186BE7D-27D1-4B0D-9C8B-62D7190A6FE1 wds:Q73445633-36FEC7F5-D99C-42ED-A0FB-6A0B361EB5E6 wds:Q73445633-5347082D-EA89-4FD6-B8FE-D0FCEECBC28D wds:Q73445633-5589B68E-D6DB-4FF4-B5B7-69A1CDCB723C wds:Q73445633-84087CC1-803C-4199-801C-99601173EF17 wds:Q73445633-A4B09ABE-38FD-4C3C-8C54-C3BB219B8C2F wds:Q73445633-CBE5BCF3-A981-4B3B-A678-B677A7E5C4A2 wds:Q73445633-CF88DC86-CE3E-45B9-A660-ADB46B656EDB wds:Q73445633-D84F00E1-9E37-424F-972B-40C77819D365 wds:Q73445633-DE3BCB43-3688-4F4B-A068-F21B11D218BE
author name string	A Awada S Houston J G Klijn J Schachter R Coleman M Piccart T Gamucci R Paridaens R Sylvester J Wildiers A Van Vreckem P Bruning
rdfs:label	Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over (en) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over (nl) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over (sq)
skos:prefLabel	Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over (en) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over (nl) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over (sq)
name	Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over (en) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over (nl) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over (sq)
author	wds:Q73445633-BB181E87-866C-427F-AB28-22FA909307C7
author	Laura Biganzoli
title	wds:Q73445633-D1A4267D-4463-4B0F-A18F-1D4FD04AEED3
title	Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over (en)
page(s)	wds:Q73445633-38012A5A-F72D-4342-8F0B-60F99E2BA2BA
page(s)	724-733
instance of	wds:Q73445633-5B2E93E4-F88B-4B3D-A97A-C2E0CBEFF4AD
instance of	scholarly article
main subject	wds:Q73445633-6914AEC7-779F-4FBB-BB5D-9E54EF5B3031 wds:Q73445633-B5284CEA-D661-48BE-8F71-F1B39B0CC1B8 wds:Q73445633-D6672D90-4FFF-4DD0-81CA-F946DCB5CC9C wds:Q73445633-EFCF5A24-5AD4-45D2-9204-7D7C1AEBB069
main subject	wd:Q18936 wd:Q423762 chemotherapy metastatic breast cancer
PubMed ID	wds:Q73445633-93D7AB39-9FFC-4CAB-952F-0628EBB3AE9C
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10673513
PubMed ID	10673513
published in	wds:Q73445633-10F5BE8E-6443-4D12-858C-D0D4FAFCE263
published in	Journal of Clinical Oncology
issue	wds:Q73445633-E46F2873-BFD3-47E2-B890-C67A52FC5C0E
volume	wds:Q73445633-B1C1FF0D-81B5-46EB-B9A6-ABE71EEF14B5
issue	4
volume	18
DOI	wds:Q73445633-AAB52C09-E7AE-4EC8-91D2-0193840F64E5
DOI	http://dx.doi.org/10.1200/JCO.2000.18.4.724
DOI	10.1200/JCO.2000.18.4.724
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73445633
is cites work of	Selection of adjuvant chemotherapy for treatment of node-positive breast cancer Progression-free survival as a surrogate endpoint in advanced breast cancer Taxane containing regimens for metastatic breast cancer Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer US Food and Drug Administration approval overview in metastatic breast cancer Taxane containing regimens for metastatic breast cancer Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Use and abuse of taxanes in the management of metastatic breast cancer. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial Topoisomerase II inhibitors Chemotherapy for metastatic breast cancer-report of a European expert panel Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure Docetaxel: a review of its use in metastatic breast cancer Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study Generation and functional assessment of 3D multicellular spheroids in droplet based microfluidics platform Risks and benefits of taxanes in breast and ovarian cancer Modeling the relationship between progression-free survival and overall survival: the phase II/III trial CDK5RAP2 is required for spindle checkpoint function Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software